intravitreal anti-vascular endothelial growth factor use in France during COVID-19 pandemic

What The Study Did:

This study quantified changes in the use of intravitreal (IVT) anti-vascular endothelial growth factors (anti-VEGF), the main treatment for retinal vascular abnormalities, since the COVID-19 pandemic started in France.

Authors:

Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance in Saint-Denis, France, is the corresponding author.

To access the embargoed study:

Visit our For The Media website at this link

https:/

(doi:10.1001/jamaophthalmol.2020.5594)

Editor’s Note:

Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory:

The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

121720